Between 2023 and 2026, real-world data from 972 patients evaluated by UVA Health researchers reveals that histotripsy—a noninvasive, sound-wave cancer treatment—achieved low procedural toxicity but recorded an 11% mortality rate within 30 days.
Systemic Disease Progression Outpaces Local Liver Treatment
- Histotripsy Explained: A noninvasive technique using focused sound waves to create air bubbles that destroy liver tumors without surgical incisions.
- The 30-Day Paradox: While the procedure avoids hospital stays and shows minimal laboratory toxicity, nearly 70% of treated patients had cancer spreading to the liver from elsewhere in the body, including the pancreas, meaning systemic disease progression often outpaces local liver treatment.
- Patient Selection: Clinical consensus now shifts from asking whether the technology works technically to identifying exactly which patients are most likely to live long enough and have the right type of cancer to benefit.
Evaluating Sound-Wave Tumor Destruction in Clinical Practice
Histotripsy works by directing focused sound waves into diseased liver tissue. This energy creates air bubbles that destroy cancer cells. Early clinical studies in carefully selected patients demonstrated technical effectiveness and strong safety profiles, prompting the U.S. Food and Drug Administration to clear the procedure in 2023. However, moving from controlled trials to broader real-world clinical practice exposed complex variables regarding patient baseline health.
Led by Allan Tsung, surgical oncologist and chair of UVA Health’s Department of Surgery, researchers reviewed outcomes for 972 patients treated between 2023 and 2026. The evaluation tracked post-procedure survival, liver function markers, and kidney injury risks. While laboratory toxicity remained low and immediate complications were minimal, the 11% 30-day mortality rate demanded a deeper epidemiological appraisal of who receives the therapy.
| Clinical Parameter | Real-World Data (UVA Health Cohort) | Initial Trial Expectations |
|---|---|---|
| Total Patients Evaluated | 972 patients (2023–2026) | Smaller, carefully selected patients |
| Procedural Toxicity | Low rates of laboratory and procedural toxicity | Encouraging procedural safety profile |
| 30-Day Mortality | 11% of patients died within one month | Primarily focused on technical success |
| Metastatic Burden | Nearly 70% had cancer spread to the liver from elsewhere | Localized primary or limited liver disease |
The Burden of Advanced Metastatic Disease
Nearly 70% of the procedures analyzed in the study involved patients whose cancer had spread to the liver from distant primary sites, including pancreatic cancer. When systemic metastatic disease is active outside the liver, destroying hepatic tumors may offer little meaningful benefit if cancer elsewhere in the body continues to progress. As ncbi.nlm.nih.gov notes in parallel studies regarding contemporary patterns of care for de novo metastatic cancers, treatment planning for patients with imminently fatal disease requires balancing factors such as performance status, organ function, and symptom burden.
Patients diagnosed with de novo metastatic cancer generally are urged to make decisions about treatment soon after diagnosis. Yet, survival benefits may not apply to patients who are extremely ill at the time of diagnosis. The research team emphasizes that procedure timing is paramount.
What surprised us was the contrast between how well patients tolerated the procedure itself and the number of patients who died within 30 days,
said Allan Tsung.
That does not mean histotripsy caused those deaths. What it does tell us is that we need to better understand which patients are most likely to live long enough and have the right type of cancer to meaningfully benefit from this treatment.
Advanced Disease Patients Should Discuss Palliative Care Options
Histotripsy is not appropriate for every cancer patient. Individuals with advanced disease where life expectancy is limited should discuss palliative or hospice care options with their oncology care team rather than pursuing localized tumor ablation.
Shifting the Clinical Paradigm Toward Patient Selection
The transition of innovative medical technologies from controlled academic trials into everyday hospital settings often reveals disparities between technical feasibility and therapeutic impact. Histotripsy allows patients to avoid a hospital stay. Yet, the real-world data shows that technical success does not equal overall survival benefit.
Researchers conclude that future protocols must prioritize rigorous screening metrics. By refining patient selection criteria—focusing on who is most likely to live long enough and the extent of extra-hepatic disease—clinicians can ensure that advanced sound-wave therapy is deployed when it offers a genuine trajectory toward meaningful benefit.
References
- Sears, O., Bitar, E.R., Cummins, K.C., Blatz, N., Cook, M., Sheeran, D., & Tsung, A. (2026). Early Outcomes of Histotripsy for Liver Tumors in US Clinical Practice. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.27493
- National Center for Biotechnology Information (NCBI). Treatment Patterns Among De Novo Metastatic Cancer Patients. PMC6521896.
